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Abstract
 
Antiviral roles of natural killer (NK) cell subsets were examined in C57BL/6 mice infected
with murine cytomegalovirus (MCMV) and other viruses, including lymphocytic choriomen-
ingitis virus (LCMV), vaccinia virus (VV), and mouse hepatitis virus (MHV). Each virus vigor-
ously induced an NK cell infiltrate into the peritoneal cavity and liver, causing some redistribu-
tions of NK cell subsets defined by monoclonal antibody (mAb) directed against Ly49A, C/I,
D, and G2. Striking results were seen with a mAb (1F8) reactive with the positively signaling
molecule Ly49H, present in MCMV-resistant C57BL/6 mice. mAb 1F8 also stains Ly49 C and
I, but exclusion of those reactivities with mAb 5E6, which recognizes Ly49 C and I, indicated
 
that Ly49H
 
 
 
 cells infiltrated the peritoneal cavity and liver and were particularly effective at
 
synthesizing interferon 
 
 
 
. Depletion of 1F8
 
 
 
 but not 5E6
 
 
 
 cells in vivo by mAb injections en-
hanced MCMV titers by 20-1,000-fold in the spleen and approximately fivefold in the liver.
Titers of LCMV or VV were not enhanced. These anti-MCMV effects were attributed to pro-
totypical NK1.1
 
 
 
CD3
 
 
 
 NK cells and not to NK1.1
 
 
 
CD3
 
 
 
 “NK/T” cells. This is the first ev-
idence that control of a virus infection in vivo is mediated by a distinct NK cell subset.
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Introduction
 
NK cells represent up to 15% of peripheral blood lympho-
cytes and can reach high concentrations at sites of inflam-
mation, but despite their discovery 25 yr ago, convincing
evidence for their importance has only been established in a
limited number of systems (1). Although proposed to me-
diate immunoregulatory and tumor surveillance functions,
their primary role, like that of the rest of the immune sys-
tem, is most likely to combat infectious agents. To do so,
they may need the capacity to selectively recognize and at-
tack infected host cells or else to nonselectively respond to
stimuli and mediate effector function by the nonspecific re-
lease of cytokines. An understanding of the molecular
mechanisms of NK cell recognition of target cells has been
developed after the identification of a series of families of
 
NK cell receptor (NKR)
 
*
 
 molecules that can deliver either
negative or positive signals to NK cells on encounter with a
target (2–4). Many of these receptor molecules recognize
MHC class I antigens, but the possibility remains that some
might also recognize other cell surface structures.
One family of mouse NKR molecules is the Ly49
group, which now consists of a variety of C-type lectin
molecules, designated A through W. The Ly49 gene family
maps near the positive-triggering molecule NKR-P1 (de-
fined by mAb NK1.1) in the area of chromosome 6,
known as the NK cell complex (5, 6). Of note is that ge-
netic resistance and susceptibility to murine cytomegalovi-
rus (MCMV) maps within this region at a locus designated
 
Cmv-1 
 
(7). The evidence implicating NK cells in the con-
trol of MCMV infection is stronger than for any other in-
fectious agent. Suckling mice are very sensitive to MCMV
infection, but a level of resistance develops at about the
third week of age, correlating not only with the develop-
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30
 
Control of MCMV by an NK Cell Subset
 
ment of NK cell activity but also with the expression of
Ly49 molecules on a high frequency of NK cells (8, 9).
Reconstitution of suckling mice with NK cells in adult
splenocytes or with IL-2–activated, cultured lymphokine-
activated NK cells confers resistance to infection (10, 11).
Depletion of NK cells with anti-NK cell Abs in normal,
athymic nude, or severe combined immunodeficiency
mice results in substantially elevated titers of MCMV early
in infection (12–16). Mice with genetic deficiencies in NK
cell function are very sensitive to MCMV (17). Together
these experiments indicate that classically defined CD3
 
 
 
NK cells, as opposed to NK/T cells, provide innate immu-
nity to MCMV.
NK cells regulate MCMV infection by different pre-
ferred mechanisms in different organs. In the liver, MCMV
is controlled by IFN-
 
 
 
, possibly acting through a nitric ox-
ide synthase intermediate (18, 19). The chemokine MIP-
1
 
 
 
 attracts NK cells into the liver (20). MCMV induces
relatively high levels of IL-12, which serves to induce se-
cretion of IFN-
 
 
 
 from the highly activated NK cells (18).
In the spleen, the NK cell–mediated control of MCMV is
less dependent on IFN-
 
 
 
 and more dependent on perforin
(19). The presumption is that a cytotoxic mechanism regu-
lates MCMV in the spleen, but it is not known why these
organs differ mechanistically in their control of MCMV.
Of note is that the 
 
Cmv-1
 
 locus appears to regulate MCMV
synthesis more in the spleen than in the liver, suggesting
that it might relate to a cytotoxic mechanism (7).
The mapping of the 
 
Cmv-1
 
 gene in proximity to the
Ly49 loci in C57BL/6 mice has previously led us to ques-
tion whether NK cell subsets expressing a distinct Ly49
molecule might mediate resistance to MCMV. No NK cell
subset has ever been shown to selectively regulate the syn-
thesis of a virus or any other pathogen in vivo. Analyses of
cells expressing different Ly49 molecules have been com-
plicated by the fact that each NK cell expresses several dif-
ferent types of Ly49 molecules and that some of the Abs
directed against one molecule cross-react with other
molecules. To date, Ly49 molecules defined by four differ-
ent commercially available Abs have been examined in the
MCMV system: Ly49A, D, G2, and C and I, which is a
pair detected by the same mAb (5E6; reference 21). No se-
lective role for either subset could be shown in the control
of infection (22). Mice depleted of NK subsets in vivo with
mAb to Ly49 A, D, C/I, or G2, or with combinations of
two or three anti-Ly49 mAbs tended to be just as resistant
to MCMV as untreated mice. Adoptive transfers of any of
these subsets into suckling mice protected them against
MCMV (22). This indicated that neither of these Ly49
molecules defined a subset of NK cells required for resis-
tance to MCMV.
We report here that an NK cell subset detected by the
anti-Ly49 mAb 1F8 is essential for resistance to MCMV in
C57BL/6 mice. This mAb was generated against Ly49H, a
positively signaling Ly49 molecule (4). It cross-reacts with
Ly49C and I, which is detected by the 5E6 mAb. We report
here that the 1F8
 
 
 
(C/I/H) 5E6
 
 
 
(C/I) NK cell subset is es-
sential for control of MCMV infection in C57BL/6 mice.
 
Materials and Methods
 
Mice.
 
Most experiments used 5–10-wk-old C57BL/6J
(H2
 
b
 
) male mice; some experiments used Balb/cByJ (H2
 
d
 
) mice
or C57BL/6 mice lacking all T cells as a consequence of genetic
recombination deleting the TCR-â and ä genes (T cell knock-
out [KO] mice). All mice were purchased from The Jackson
Laboratory.
 
Viruses.
 
The Smith strain of MCMV was propagated in vivo
in salivary glands of Balb/c mice (14). Infected salivary gland ho-
mogenates were diluted in HBSS (Life Technologies) and, de-
pending on the experiment, mice were inoculated intraperito-
neally with 3 
 
  
 
10
 
3
 
 to 2 
 
 
 
 10
 
4
 
 plaque-forming units (PFUs) of
MCMV, as titrated on mouse embryonic fibroblast monolayers.
The Armstrong strain of lymphocytic choriomeningitis virus
(LCMV) and its more widely disseminating clone 13 variant were
propagated in baby hamster kidney cells, and 
 
 
 
5 
 
 
 
 10
 
4
 
 PFUs, as
titrated on vero cell monolayers, were used for inoculations (23).
Vaccinia virus (VV), WR strain, was propagated in L929 cells,
purified over sucrose gradients, and inoculated at doses of 10
 
6
 
PFUs, as titrated on vero cells (24). Mouse hepatitis virus
(MHV), strain A-59, was propagated in L929 cells and, unless
otherwise stated, was inoculated into mice at doses of 7 
 
 
 
 10
 
5
 
PFUs, as assayed on L929 cell monolayers (25).
 
Preparation of mAb 1F8 to Ly49H.
 
The amino acid sequences
of Ly49 C, I, and H are very similar to each other and differ sig-
nificantly from other Ly49 molecules (26). mAb 1F8, a rat IgG2a
with high reactivity to Ly49H, was prepared while attempting to
generate an Ly49C-specific mAb. F334 rats were inoculated in-
trasplenically with 100 mg of a KLH-bound Ly49C amino acid
sequence (CRPSNETLEYIKREQDRWDSKTKTVLD) that
differed from Ly49I by a few amino acids. 1 mo later equal vol-
umes of CFA and 100 mg of the peptide KLH were injected sub-
cutaneously, followed by three additional injections at biweekly
intervals. Spleen cells were removed and fused with SP2/0 my-
eloma cells to make mAbs. mAb specificity was screened on
Bw5147 cells transfected with Ly49C or Ly49I or on RNK-16
cells transfected with Ly49H. All of the Ly49-specific mAb gen-
erated cross-reacted with Ly49 C, I, and H, but mAb 1F8 was the
most potent and was useful for depletions in vivo. mAb 1F8 does
not recognize Ly49 A, D, or G2. Limitations of this mAb are its
cross-reactivity with Ly49 C and I, but it can be used to measure
Ly49H by using it in concert with mAb 5E6, which reacts with
Ly49 C and I, but not H. Another recently published mAb
to Ly49H cross-reacts with Ly49I (27). To date there is no available
mAb that exclusively recognizes Ly49H.
 
Depletion of NK Cells In Vivo.
 
Mice were depleted of NK
cells by a single intraperitoneal inoculation of 25–200 
 
 
 
g of col-
umn-purified mAb 1F8 6–24 h before infection with virus. As
controls, mice were inoculated with 100 
 
 
 
l PBS containing 200
 
 
 
g of mAb 5E6, which recognizes Ly49 C/I, or with a dose of
mAb to NK1.1 (PK136) titrated to eliminate LCMV-induced
NK cell but not CTL activity (12). Some control mice were in-
oculated with PBS which, as we showed previously, results in
MCMV titers indistinguishable from inoculations with mAb to
Ly49A, D, G2, or C/I (22).
 
Isolation of Leukocytes.
 
Spleens were ground between glass
microscope slides, and spleen leukocytes were isolated by treat-
ment with 0.84% NH
 
4
 
Cl to lyse erythrocytes. Peritoneal cells
were isolated by lavaging the peritoneal cavity with 10 ml of
RPMI 1640 (Life Technologies). Liver leukocytes were isolated
by flushing blood from the liver by injecting media through the
portal vein, crushing the liver in a tissue grinder, treating with
type II collagenase (Sigma-Aldrich) and type I DNase (Sigma- 
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Aldrich), and harvesting the leukocyte layer from a metrizamide
(Sigma-Aldrich) density gradient, as described previously (28).
 
Immunofluorescence Staining and Intracellular IFN-
 
 
 
 Assay.
 
Leu-
kocytes were isolated and stained for the intracellular accumula-
tion of IFN-
 
 
 
 using reagents and the protocol of BD PharMin-
gen. One million cells were cultured in Falcon 96-well
U-bottomed plates (Becton Dickinson) with RPMI media (Life
Technologies) containing GolgiPlug (BD PharMingen) at 0.2 
 
 
 
l
per sample in the presence or absence of 50 ng/ml PMA (Sigma-
Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h at
37
 
 
 
C. Unless otherwise stated, data are shown for samples incu-
bated in the absence of PMA and ionomycin. Cells were washed
using FACS
 
®
 
 buffer (PBS with 2% FCS and 0.02% sodium azide)
and incubated for 15 min at 4
 
 
 
C in 100 
 
 
 
l of FACS
 
®
 
 buffer plus
9 
 
 
 
l normal mouse serum and 1 
 
 
 
l of anti-Fc
 
 
 
II receptor Ab to
block nonspecific staining. Cells were washed and incubated at
4
 
 
 
C for 30 min with combinations of anti-NK1.1-PE (BD
PharMingen), anti-CD3-PerCP (BD PharMingen), and various
anti-Ly49 mAb or isotype controls. These were isotype control
mouse (m) IgG2a-FITC (BD PharMingen), isotype control rat (r)
IgG2a-FITC (BD PharMingen), anti-Ly49D-FITC (a gift from
Dr. John Ortaldo, National Cancer Institute, Frederick, MD),
anti-Ly49G2-FITC (BD PharMingen), anti-Ly49C-biotin (BD
PharMingen), and anti-Ly49H (1F8)-FITC produced by us.
Samples were washed twice and, if necessary, were incubated
with SA-PerCP (BD PharMingen) for 30 min at 4
 
 
 
C. Otherwise
they were fixed and permeabilized using 100 
 
 
 
l of cytofix/cyto-
perm solution for 20 min at 4
 
 
 
C. After fixation the samples were
washed twice using perm/wash solution (200 
 
 
 
l per sample) and
stained with rat IgG1-APC mAb to mouse IFN-
 
 
 
 (BD PharMin-
gen) or with a control rat IgG1-APC (BD PharMingen) for 30
min at 4
 
 
 
C. Samples were then washed two times using perm/
wash and once using FACS
 
®
 
 buffer before being transferred to
tubes (model 2008; Falcon) for analysis on either a FACS
 
®
 
 440
(Becton Dickinson) or a FACStar™ Plus (Becton Dickinson).
For these analyses, 60–80,000 events were calculated, ensuring a
sizable NK cell population for a valid analysis of NK subsets. All
experiments used relevant control mAbs with isotypes equivalent
to the anti-Ly49 and anti–IFN-
 
 
 
 mAb, but in some figures the
negative isotype control plots are not shown to maintain clarity
and simplicity of the figure.
 
Results
 
NK Cell Subset Distribution during Viral Infections.
 
The
NK cell response against MCMV (Fig. 1 A), MHV (Fig. 1
A), VV (Fig. 1 B), and a disseminating strain of LCMV
(clone 13) (Fig. 1 B) was examined initially during the first
3 d of infection of C57BL/6 mice. Here spleen, peritoneal
cavity, and liver NK cells, defined as NK1.1
 
 
 
CD3
 
 
 
, were
quantified, and their total numbers and percentages within
lymphocyte-gated populations were enumerated, as shown
in the vertical bars in Fig. 1. Each virus infection initially
caused a slight transient decrease in NK cell number and
percent in the spleen, but each virus induced a substantial
increase in NK cell number and percent in the peritoneal
cavity, which was the site of viral inoculation. This increase
in NK cells in the peritoneal exudate cells (PECs) with all
of these viruses had been reported by us in the 1980s, when
large granular lymphocyte morphology and Ab to asialo
GM1 was used to define NK cells (29, 30). NK 1.1 is a
 
more specific NK cell marker, particularly when used on
lymphocyte-gated cells that fail to stain with anti-CD3. It is
now known that there are significant populations of “NK/
T” cells that costain with anti-NK1.1 and anti-CD3, and it
is important to make those distinctions. In addition, we
have found that VV induces a strong 
 
  
 
 T cell response and
that 
 
 
 
1/3 of those 
 
  
 
 T cells stain with anti-NK1.1 (31).
Each virus also stimulated an increase in the total number
and percentage of NK cells in the liver, a result also previ-
ously noted by us using less definitive techniques (28).
These increases in NK cell numbers and percentages are
very reproducible findings, though the degree and kinetics
of the responses vary somewhat with virus dose. We have
previously shown that NK cells migrate into areas of virus
infection and undergo division in those areas (28–30).
We questioned whether commercially available Abs to
Ly49 molecules (A, C/I, D, G2) could detect qualitative
differences in NK cell responses between organs and be-
tween viruses. These experiments showed a great deal of
animal-to-animal variability, but some conclusions could
be drawn. The first conclusion is that only a low percent-
age of resident NK cells in the liver before infection ex-
pressed these Ly49 antigens, with the exception of Ly49
C/I, which was lower but in the range of spleen and PEC
percentages. A much higher frequency of the infiltrating
NK cell population in the liver after virus infection ex-
pressed other Ly49 markers, in particular Ly49 D and G2,
at frequencies more in line with other compartments. A
second major conclusion is that within a mouse the rela-
tive frequencies of NK cells coexpressing Ly49 molecules
change in relation to each other in different organs and at
different times after infection. This indicates that these
NK cell subsets are responding to signals induced by the
viral infections differently, though it is less clear how dif-
ferent one virus was from the other at inducing these
changes in NK cell distribution. In this experiment it ap-
peared that all four viruses induced drops in Ly49C per-
centages in the spleen and rises in the PECs. Ly49G2 per-
centages rose in every organ with every infection. These
observations were previously noted by us in more exten-
sive analyses with MCMV (22). A consistent result seen
by us in three experiments was that the ratio of Ly49G2
 
 
 
to Ly49C/I
 
 
 
 liver NK cells at 3 d after infection was high
(often 
 
 
 
2:1) after infection with MCMV, LCMV, or
MHV, but the frequencies of Ly49G2
 
 
 
 and Ly49C/I
 
 
 
liver NK cells were about equal after VV infection (Fig. 1,
and data not shown). These subtle differences suggest
some selectivity in the NK cell responses to different vi-
ruses.
Although each of these viruses activated NK cell popula-
tions and stimulated their redistribution, it is only MCMV
that has been consistently shown to be highly regulated by
NK cells (12–14, 16, 17, 32). Inoculation of mice with Ab
to NK1.1 results in significantly higher titers of MCMV in
the spleen and liver by 3 d after infection (15, 16). We pre-
viously showed that depletion of any one or two NK cell
subsets by inoculating mice with Abs to Ly49A, C/I, D, or
G2 had no effect on MCMV synthesis, even though some 
32
 
Control of MCMV by an NK Cell Subset 
33
 
Daniels et al.
 
of these mAb combinations reacted with 
 
 
 
70% of the NK
cells before infection (22). This indicates that, while viral
infections induce redistributions of NK cell subsets, no
subset defined by the commercially available Abs is essen-
tial for the control of MCMV infection. Therefore, we
questioned whether other Ly49 molecules might be of
unique significance in controlling viral infections and re-
port below on studies with mAb 1F8, recognizing Ly49H,
but cross-reacting with Ly49 C and I, molecules detected
by the 5E6 mAb.
 
Strain Distribution of 1F8 Reactivity.
 
The resistance of
mice to MCMV is very dependent on their genetic back-
ground (7). Balb/c mice are highly susceptible, and
C57BL/6 mice are resistant. In this study we found that by
day 4 after infection the Balb/c mice had 
 
 
 
100-fold more
MCMV PFUs in their spleens than did the C57BL/6
strain. Fig. 2 shows the expression of antigens detected by
mAb 1F8 (C/I/H) and 5E6 (C/I) on splenocytes of these
mice, all gated on cells expressing the pan NK cell marker
DX-5. NK cells from the highly sensitive Balb/c strain
stained with 5E6, but did not express the Ly49H subset, as
defined by 1F8
 
 
 
5E6
 
 
 
cells. In contrast, NK cells from
C57BL/6 mice had sizable proportions of both 1F8
 
 
 
5E6
 
 
 
and 1F8
 
 
 
5E6
 
 
 
 populations. Thus, the expression of Ly49H
(defined as 1F8
 
 
 
5E6
 
 
 
) on NK cells appeared to correlate
with the resistance of mice to MCMV.
 
Accumulation of Ly49H
 
 
 
 Cells at Sites of MCMV
Infection.
 
Mice were inoculated intraperitoneally with
MCMV and examined for the accumulation of NK cell
subsets costaining with mAb 1F8. Fig. 3 A shows that
MCMV induced a substantial increase in the number of
NK1.1
 
 
 
CD3
 
 
 
 NK cells and that there was a substantial to-
tal number and proportional increase in the 1F8
 
 
 
 NK cell
subset in the liver and PECs at days 2 and 3 after infection.
Fig. 3 B shows that a high proportion of the NK cells infil-
trating the MCMV-infected liver by day 2 stained with
 
mAb 1F8 but not 5E6, suggesting that this was indeed an
infiltration by Ly49H
 
 
 
 cells. There also was a significant
increase in 1F8
 
 
 
5E6
 
 
 
 cells, but it is not possible to deter-
mine whether these cells also coexpressed Ly49H.
 
Selective Synthesis of IFN-
 
 
 
 by Ly49H
 
 
 
 Cells.
 
We noted
that, in the presence of brefeldin A, substantial proportions
(i.e. 
 
 
 
25%) of the NK cells from MCMV-infected mice
spontaneously produce intracellular IFN-
 
 
 
 if allowed to in-
cubate in the milieu of leukocytes from virus-infected tis-
sue. For these assays to be optimal, the cells were quickly
harvested and incubated without being put on ice. Usually
this intracellular IFN assay is done with lymphocytes re-
ceiving an in vitro stimulus with immunogenic peptides
(for T cells) or with nonspecific stimulators, such as PMA
and ionomycin (24, 33); this may mean that something in
this cellular milieu continued to stimulate the NK cells.
Because of the unusual nature of this assay, several controls,
in addition to the isotype controls for the anti–IFN-
 
 
 
 mAb
used in every assay, were run to ensure that synthesis of
IFN-
 
 
 
 was being observed. Using splenocytes from day 2
MCMV-infected mice as a source of IFN-
 
 
 
–producing
cells, threefold molar excess of unlabeled anti-IFN-
 
  
 
mAb
reduced the frequency of anti–IFN- –staining NK cells
from 23 to 7.6%, and the mean fluorescent intensity of the
remaining and very weakly staining positive cells was re-
duced from 638 to 120. This mAb did not block the ability
of (nonNK cell) splenocytes to synthesize intracellular
TNF-  (positive control   0.8%; anti–IFN-  mAb-
blocked   0.7%). Similarly, incubation of the anti–IFN- 
mAb with 0.8  g/ml IFN-  during the IFN-  assay re-
duced the frequency of IFN-  staining from 20 to 7.5, and
reduced the mean fluorescent intensity of the remaining
positive cells from 736 to 473, without reducing the stain-
ing against TNF- . We conclude that this assay is indeed
detecting IFN-  synthesis and that it is revealing a high fre-
quency of NK cells that produce IFN-  when kept in the
Figure 1. Dynamics of the NK cell response to virus infections. Spleen, PECs, and liver leukocyte populations were isolated and examined daily after
infections of C57BL/6 mice with MCMV (A), MHV (A), VV (B), and LCMV clone 13 (B). Line diagrams depict the percentage of gated NK1.1 CD3 
NK cells reacting with mAb to Ly49A, C/I, D, or G2, or with appropriate isotype control Abs. To the left of each line diagram are vertical bars depicting
the percentage of NK1.1 CD3  cells in lymphocyte-gated fractions (top) and the total number of NK1.1 CD3  cells per organ (bottom).
Figure 2. Expression of Ly49H on NK cells from differ-
ent strains of mice. C57BL/6 and Balb/c splenocytes were
stained with mAb DX-5 (as a pan NK cell marker that
would recognize cells from each strain), anti-CD3, and mAb
1F8 (anti-Ly49 C/I/H) and mAb 5E6 (anti-Ly49 C/I). Dia-
grams depict the staining of gated DX-5 CD3  lympho-
cytes and isotype controls for mAb 5E6 and 1F8.34 Control of MCMV by an NK Cell Subset
milieu of leukocytes from virus-infected mice. We exam-
ined IFN- –producing NK cells over the first 3 d of
MCMV infection and found a sharp peak of production at
2 d after infection, in agreement with other publications
using different types of techniques (18).
NK1.1 CD3  Lymphocytes Were Analyzed for IFN- 
Production in Different Ly49 Subsets.  Fig. 4 shows that,
whereas no spontaneous IFN-  production was made by
uninfected splenocytes, PECs, or liver leukocytes, substan-
tial levels were made in all compartments 2 d after MCMV
infection. Substantially higher proportions of NK cells
made IFN-  in the liver and PECs, in comparison to the
spleen, perhaps because the liver is a site for substantial
MCMV replication and the peritoneal cavity was the initial
site of inoculation, and these sites may be enriched for
IFN- –promoting factors, such as IL-12 (34). In 17 exper-
iments the average percent of NK1.1 CD3  splenocytes
spontaneously producing IFN-  after MCMV infection
was 34   16%; in 16 experiments the average in the PECs
was 35   13%; in six experiments with liver leukocytes the
average number was 42   14%.
Cells staining with mAb 1F8 accounted for much higher
proportions of IFN- –producing cells than cells not react-
ing with mAb 1F8 in either the spleen or PECs (Figs. 4 A
and 5); in fact, 1F8  cells tend to be very poor at IFN- 
production in those compartments. It is also noteworthy, as
shown in Fig. 3, that the proportion of NK cells in the
PECs and liver expressing the 1F8 antigens increased dra-
matically after infection. Thus,  80% of the IFN- –pro-
ducing cells from these sites stained with mAb 1F8. Fig. 4
B shows IFN-  production by spleen NK cell subsets
stained with the 5E6 and 1F8 Abs. It shows that the
5E6 1F8  staining population, presumably those express-
ing Ly49 H, were preferentially enriched in their produc-
tion of IFN- . In about half of the experiments 5E6  cells
or 5E6 1F8  cells were somewhat enriched for IFN- 
production, particularly from the PECs, but it is not possi-
ble to know if those cells coexpressed Ly49H. In all techni-
cally satisfactory experiments studied, however, IFN- 
production was substantially enriched in the 1F8  (seven
experiments) and in the 1F8 5E6  (five experiments) NK
cell populations, particularly in contrast to the populations
not staining with 5E6 or 1F8.
Additional experiments were done to determine
whether there was enrichment for IFN-  production in
NK cells expressing other Ly49 antigens. Fig. 5 shows that
similar proportions of Ly49D  and Ly49D  cells made
IFN-  and similar proportions of Ly49G2  and Ly49G2 
cells made IFN- , indicating no enrichment in IFN-  pro-
duction in cells expressing those Ly49 markers. In other
experiments we tested Ly49A  and A  cells, finding no
proportional differences in those populations either (data
not shown). Fig. 5 also shows that splenocytes staining with
mAb 5E6 (Ly49C/I) produced similar levels of IFN-  as
Figure 3. Reactivity of leukocytes with mAb 1F8 after MCMV infection. (A)
C57BL/6 mice were inoculated intraperitoneally with MCMV and the total
number of gated NK1.1 CD3  NK cells costaining with mAb 1F8 was moni-
tored by multiplying the percentage of positively staining cells by the total num-
ber or organ lymphocytes. (B) The experiment was designed as in A, except that
at day 2 after infection, NK1.1 CD3 –gated liver NK cells were stained with
both mAb 5E6 (anti-Ly49C/I) and 1F8 (anti-Ly49C/I/H). The 5E6 1F8  cells
are presumed to express Ly49H but not Ly49 C or I.35 Daniels et al.
those not expressing that marker, but in the PECs, 5E6 
cells tend to have increased proportions of IFN- –produc-
ing cells. Over 80% of the IFN- –producing splenocytes
and PECs in this experiment expressed reactivity with the
1F8 mAb. These experiments suggest that the Ly49H sub-
set may be particularly effective at making IFN-  after
MCMV infection.
Stimulation of 1F8  Cells by Other Viruses. We tested
whether the profound stimulation of Ly49H  NK cells
was unique to MCMV or whether it was a general prop-
erty of viral infections. As with MCMV infection, the
proportions of 1F8  NK cells and of Ly49H  (1F8 ,
5E6 ) NK cells increased in the organs of mice infected
with LCMV clone 13, MHV, or VV. In one experi-
ment, 17% of the resident PEC NK cells were 1F8 
5E6 , and this increased to 31, 29, and 37% 2 d after
infection with LCMV, MHV, and VV, respectively (Fig.
6); 6.7% of the resident NK cells in the liver were
1F8 5E6 , and this, respectively, increased to 36, 35,
and 40% by 2 d after infection. LCMV and MHV were
also examined at 3 d after infection and similarly in-
duced higher levels of 1F8 5E6  (Ly49H)-positive cells
in the PECs and liver by 3 d after infection (data not
shown). Thus, this NK cell subset, presumed to be
Ly49H , appeared to respond well to all tested virus in-
fections.
Figure 4. Pronounced IFN-  production by NK cells
reacting with mAb 1F8. (A) Spleen, PECs, or liver lym-
phocytes were monitored for spontaneous IFN-  produc-
tion before or 2 d after intraperitoneal infection with
MCMV. The plots show NK1.1 CD3 –gated NK cells
reacting with mAb 1F8 and producing intracellular IFN- 
in the presence of brefeldin A. Isotype control mAbs for
IFN-  showed virtually no ( 1%) reactivity for any of the
samples and are displayed for the MCMV-infected group.
(B) NK1.1 –gated spleen NK cells 2 d after MCMV infec-
tion were costained with mAb 5E6 and 1F8 and tested for
IFN-  production.36 Control of MCMV by an NK Cell Subset
IFN-  Production Was Examined in NK Cells Elicited by the
Different Viruses. Under these conditions of infection,
MCMV elicited more spontaneous IFN-  production from
spleen, PECs, and liver NK cells at 2 d after infection than
did the other viruses, as discussed earlier, presented in Fig. 4
A, and as shown in a control representative experiment for
MCMV in Table I. We did not systematically analyze
whether these other viruses would induce substantially
higher levels of IFN-  from NK cells under conditions of
different doses or times of infection, but it is noteworthy
that none induced as high a proportion of NK cells produc-
ing IFN-  as MCMV under the tested conditions, which,
as shown in Fig. 1, stimulated strong NK cell responses.
Nevertheless, all viruses did stimulate spontaneous IFN- 
production from some of the NK cells. Of note is that we
did not observe spontaneous IFN-  production by NK
cells from mice treated with the type I IFN inducer and
NK cell activator poly I:C (data not shown). It has been
published previously that NK cells from MCMV-infected
but not LCMV-infected mice produce IFN- , and this has
been linked to differences in IL-12 production (35). Here
we do see quantitative differences between the MCMV-
and LCMV-induced NK cells, but substantial numbers of
LCMV-induced NK cells clearly synthesized IFN- .
We questioned whether the IFN- –producing NK cells
elicited by these different viruses were also biased in their
expression of 1F8. Experiment 1 in Table I compares IFN- 
production in response to either of the two LCMV
strains with MCMV, and even though the total IFN-  re-
sponse was much lower, the LCMV-induced NK cells had
Figure 5. Lack of selective
IFN-  production by Ly49D- or
Ly49G2-expressing NK cells.
Gated NK1.1 CD3  NK cells
from the spleens and PECs of 2-d
MCMV-infected C57BL/6 mice
were stained with Abs to Ly49D,
G2, C/I (mAb 5E6), or C/I/H
(mAb 1F8) and tested for sponta-
neous IFN-  production. Isotype
controls for the Ly49 mAb are
displayed. Isotype controls for
the IFN-  Ab were  1%, as
seen in Fig. 4.
Figure 6. Involvement of 1F8 
NK cells in the response to LCMV,
MHV, and VV. (Top) Reactivity
with mAb 5E6 and 1F8 on gated
NK1.1 CD3  lymphocytes isolated
from the peritoneal cavity of
C57BL/6 control mice or mice 2 d
after intraperitoneal infection with
LCMV clone 13, MHV, or VV.
(Middle and bottom rows) Staining
after incubation in an intracellular
IFN-  assay. (Middle) Isotype con-
trol mAb staining for mAb to IFN- 
(rIgG1-APC) and mAb 1F8
(rIgG2a-FITC) for NK1.1 CD3 –
gated lymphocytes from the same
mice. (Bottom) Reactivity of
NK1.1 CD3  lymphocytes with
mAb to IFN-  and to 1F8.37 Daniels et al.
a similar if not greater skewing of the IFN-  response
within the NK cell population defined by mAb 1F8, and
less so in that defined by mAb 5E6. A second experiment
(Table I, Exp. 2) with LCMV, MHV, and VV similarly
showed a preponderance in IFN-  responsiveness within
the cell populations defined by mAb 1F8; the peritoneal
cell data from this experiment are depicted in Fig. 6, which
shows a predominant skewing of the IFN-  response to
1F8  cells, particularly for the LCMV and VV infections.
These results suggest that the propensity of the 1F8  cells
to proportionally dominate the IFN-  response of NK cells
is profound but not specific to a given virus. It should also
be noted that 5E6  cells, which may or may not express
Ly49H, had relatively high expression of IFN-  in some of
the samples (Table I).
Selective Depletion of NK Cell Subsets In Vivo. To address
the role of Ly49 subsets in regulating MCMV infection
in vivo, mice were inoculated with mAb to Ly49 mol-
ecules in order to deplete various NK cell subsets. Our
previous studies with in vivo–depleting doses of mAb to
Ly49A, D, C/I, and G2 indicated that no one or two of
them had any effect on MCMV synthesis, and combina-
tions of three of them had little effect (22). As shown in
Fig. 4, a substantial proportion of the spleen NK cells ini-
tially react with mAb 1F8 before infection, but this is no
higher than those expressing Ly49G2 or combinations of
two of the other Abs. Of note is that a substantial number
of liver and PEC NK cells do not react with 1F8 before in-
fection. Treatment of four naive mice in two experiments
with 200  g of mAb 1F8 resulted in  50% reduction in
spleen NK cell–mediated cytotoxicity against YAC-1 ac-
tivity when measured 1 d later. Immunofluorescent studies
showed that mAb 1F8 treatment caused only a marginal
( 30%) reduction in total spleen NK cell number 1 d after
treatment, even though 1F8  NK cells could not be found
(data not shown). NK cells usually rapidly compensate for
the lack of an NK cell subset. Mice treated with mAb 1F8
and then infected with LCMV had nearly identical levels of
NK cell cytotoxicity against YAC-1 cells as untreated mice
3 d after LCMV infection, and mice treated with mAb to
1F8 and challenged with the IFN-inducer poly I:C had
levels of NK cell activity similar to poly I:C–injected con-
trol mice at 2 d after treatment (data not shown).
The above experiments indicated that residual NK cells
rapidly compensated for the deletion of the 1F8  NK cell
subset, so we examined this depletion in the context of an
MCMV infection. Fig. 7 shows the total NK cell percent-
age and the proportional distribution of NK cell subsets af-
ter mice were treated in vivo with mAb 1F8 (C/I/H) or
5E6 (C/I), infected with MCMV, and examined 4 d later.
Table I. Proportion of NK Cell IFN-  Response Mediated by 1F8  or 5E6  Cells in C57BL/6 Mice Infected with Different Viruses
Percentage of total NK cells synthesizing IFN- 
Virus Organ 1F8  IF8  (%)a 5E6  5E6  (%)b
Exp. 1 MCMV Spleen 34 21 (62) 27 28 (49)
PECs 25 8.8 (74) 16 19 (46)
LCMV-C113 Spleen 6.7 1.2 (85) 3.8 3.2 (54)
PECs 13 0.9 (94) 9.4 3.6 (72)
LCMC-Arm Spleen 6.2 2.0 (76) 3.6 3.4 (51)
PECs 12 1.2 (91) 11 5.5 (67)
Exp. 2 LCMV-C114 Spleen 2.2 0.5 (81) 1.7 0.7 (71)
PECs 13 1.5 (90) 11 4.1 (73)
Liver 4.5 1.7 (73) 3.0 5.2 (37)
MHV Spleen 4.5 0.8 (85) 1.3 2.2 (37)
PECs 1.7 1.8 (49) 1.8 2.1 (46)
Liver 12 9.2 (57) 2.9 12 (19)
VV Spleen 3.1 1.7 (65) 3.7 5.8 (39)
PECs 13 2.9 (82) 8.4 4.9 (63)
Liver 7.5 3.8 (66) 3.0 8.3 (27)
C57BL/6 mice were infected with MCMV, LCMV-clone 13, the parent LCMV Armstrong strain, MHV, or VV. At 2 d after infection leukocytes
isolated from the different tissues were examined for spontaneous synthesis of IFN- . Data shown are percentage of the NK1.1 CD3  cells that were
1F8 IFN-   and 1F8 IFN-  , or, in the second group, that were 5E6 IFN-   and 5E6-IFN-  . The percentage of cells synthesizing IFN-  within
the total NK cell population can be calculated by summing the values of each of the paired samples; minor variations in these sums between the mAb
1F8 paired groups and the mAb 5E6 paired groups are due to flow cytometric compensation differences. Exp., experiment.
aThe percentage of the IFN- –producing NK cell population that stains with mAb 1F8.
bThe percentage of the IFN- –producing NK cell population that stains with mAb 5E6.38 Control of MCMV by an NK Cell Subset
A substantial portion of NK1.1  cells remained after treat-
ment with either of the Abs. mAb 5E6 eliminated the
5E6 1F8  NK cell subset, but enriched for the 5E6 1F8 
and Ly49G2  subsets. mAb 1F8 eliminated both the 5E6 
and 1F8  cells, but enriched for the G2  cells. The fact
that in vivo administration of mAb 1F8 eliminates cells
staining with mAb 5E6 indicates that the loss of 1F8 reac-
tive cells is due to their deletion and not to a masking of
the 1F8 epitope with unlabeled mAb, because mAb 1F8
does not interfere with staining with mAb 5E6. Further,
the enrichment in the Ly49G2 subset is another indicator
that the 1F8  subset is lost and not just obscured by mAb.
This figure does illustrate how different NK cell subsets
compensate for the deletion of others.
In an additional control experiment, mAb 1F8 inocula-
tion into irradiated (C57BL/6   DBA/2) F1 hybrid host
mice did not inhibit their ability to reject C57BL/6 bone
marrow cell grafts, even though there was a loss in host NK
cells expressing Ly49 C, I, and H (unpublished observa-
tions). This means that many NK cell functions remain in-
tact in mice depleted of NK cell subsets with this mAb.
MCMV Titers in Mice Depleted of 1F8  NK Cells. De-
pletion of the 1F8  but not the 5E6  NK cell population
before infection with MCMV led to 20–1,000-fold in-
creases in spleen MCMV titers by day 3 or 4 after infection.
Five experiments, one with T cell KO mice, are shown in
Table II, illustrating this important point. Experiment 1
shows the titers in the same mice portrayed in Fig. 7. Here
treatment with mAb 1F8 resulted in  100-fold increases in
MCMV titers in the spleen and eightfold increases in the
liver. Treatment with mAb 5E6 did not significantly ele-
vate spleen titers, confirming our previous report (22). In
fact, we previously showed that treatment of mice with
mAb 5E6 in combination with mAb to Ly49D or Ly49G2
also did not enhance MCMV titers in comparison to mice
treated only with the HBSS vehicle (these experiments also
serve as good Ab injection controls; reference 22). In ex-
periment 2, treatment with mAb 1F8 is compared with
mAb to NK 1.1, which depletes virtually all NK cells.
MCMV titers were slightly but not substantially higher in
anti-NK1.1 treated– versus mAb 1F8-treated mice. In ex-
periment 4, mice were inoculated with only 50  g of mAb
1F8, which still manifested a profound effect, and in exper-
iment 5 T cell KO mice were inoculated with 25  g of
mAb and developed 100-fold increases in spleen titers. In
all, a total of seven experiments showed elevated MCMV
titers in mAb 1F8-treated mice.
In each of the seven experiments, elevated pathology
was observed in MCMV-infected mice depleted of 1F8 
cells, in comparison to infected, nondepleted controls.
Spleens from mAb 1F8-treated mice were smaller in size
and had lower cell counts than in MCMV-infected control
mice, typical of enhanced MCMV pathology. In three ex-
periments harvested at day 3 after infection, half spleen (the
other half was used for viral titrations) leukocyte counts in
control-infected mice were 6.6   1.3   107 (n   15),
whereas those in infected mAb 1F8-treated mice were
3.8   1.5   107 (n   15), P = .000007, by Student’s two-
tailed t test. In three experiments harvested at day 4 after
infection, (experiments 1, 3, and 4; Table II), half spleen
leukocyte counts for infected-control mice were 7.0  
1.3   107 (n   13), whereas the counts in mAb 1F8-treated
infected mice were 3.2    1.3    107 ( n     14), P  
.0000002. Infected mice treated with mAb 5E6 (Exp. 1,
Table II) did not have reduced leukocyte counts when
compared with infected controls. These dramatic and
Figure 7. C57BL/6 mice (n   5
per group) were inoculated with
HBSS (untreated), 200  g mAb
5E6, or 200  g mAb 1F8 and in-
fected with MCMV 6 h later. 4 d
later splenocytes were isolated.
NK1.1 CD8  cells were costained
with mAb 5E6 (Ly49C/I), 1F8
(Ly49C/I/H), anti-Ly49G2, or a
mAb isotype control. In this case
they were also costained with mAb
to CD8 (as part of an experiment
examining both T and NK cell
functions), so the NK1.1  cells may
include both NK and NK/T cells.
This figure shows selective deple-
tions of some of the Ly49 subsets
due to this mAb treatment. These
same mice were examined for viral
load, and those data are listed in ex-
periment 1 (Table II).39 Daniels et al.
highly significant reductions in spleen leukocyte count in
the mAb 1F8-treated mice are consistent with the dramatic
elevations in spleen MCMV titers observed in those mice.
Livers from mAb 1F8-treated mice displayed a greater
number of white necrotic foci on their surfaces, which is
characteristic of severe MCMV infection. Fig. 8 shows
liver sections from infected control (A and B) or mAb 1F8-
treated (C and D) mice. MCMV-infected control mice
tended to have mostly discrete small inflammatory infil-
trates around hepatocytes displaying pyknotic nuclei and
cell-rounding characteristic of MCMV infection (Fig. 8, A
and B). In contrast, large areas of necrosis, particularly near
the surface of the liver and easily distinguished by the na-
ked eye, were characteristic of the MCMV infection in
mAb 1F8-treated mice (Fig. 8, C and D). Similar increases
in pathology have been reported in mice depleted of NK
cells with pan NK cell reagents (14, 36).
Viral Specificity of the NK Cell Response. Mice treated with
mAb 1F8 were also infected with LCMV or VV as spec-
ificity controls and to ensure that the 1F8 mAb (which
was column purified) was not contaminated with an antivi-
ral agent or an agent that induces an antiviral effect, such as
type I IFN. In contrast to the results with MCMV, this
treatment did not elevate the titers of either of those vi-
ruses. This is not very surprising, as LCMV is very resistant
to NK cells (36), and the sensitivity of VV to NK cells can
be obscured by the presence of    T cells or by rapid stim-
ulation of memory    T cells (24, 31). Infectivity studies
with these viruses were therefore not continued.
In six experiments with MHV, using virus inoculum
doses ranging from 5   104 to 106 PFUs, treatment with
anti-NK1.1 only led to small increases in the titers of MHV
in the liver; average titers in control groups ranged from
3.8 to 4.9 log10 PFUs per organ, and average increase in ti-
ter in paired groups treated with anti-NK1.1 was 0.28  
0.3. Spleen titers were all  103 PFUs, and in three of six
experiments viral titers were beneath the 2 log10 detection
limit. For those reasons MHV titers were not examined in
mAb 1F8-treated mice.
Ly49 Expression on and Fate of NK/T Cells during the Host
Response to Viruses. There recently has been considerable
interest in the potential role of T cells expressing NKRs in
controlling infections and modulating host responses (33,
37–39). Any experiments done using Abs to NKRs in vivo
must be carefully interpreted due to the possibility of reac-
tions with NK/T cells rather than “true” NK cells, which
lack CD3 and T cell receptor expression. In the aforemen-
tioned experiments, where we examined NK1.1 CD3 
Table II. Enhanced MCMV Synthesis on In Vivo Depletion of 1F8  Cells
Titer (log10 PFUs per organ)
Exp.  Virus Treatment Spleen Liver
1  MCMV Control Day 4  1.0   0.0  2.1   0.2
mAb 5E6 (C/I)  1.2   0.3 2.5   0.2
mAb 1F8 (C/I/H) 4.1   0.5 3.5   0.5
2 MCMV Control Day 3  1.1   0.0 3.0   0.4
mAb NK1.1 2.9   0.3 3.7   0.6
mAb 1F8 (C/I/H) 2.3   1.0 3.3   0.7
3  MCMV Control Day 4  2.3   0.0 3.2   0.3
mAb 1F8 (C/I/H) 4.4   0.6 3.9   1.0
4  MCMV Control Day 4  1.0   0.0  2.0   0.0
maB 1F8 (C/I/H) 3.8   0.2 4.2   0.2
5 MCMV T cell KO 1.9   0.9  2.7   0.7
T cell plus mAb 1F8 3.8   0.4 3.2   0.2
6 Vaccinia Control Day 4  1.0   0.0 2.6   0.5
mAb 1F8 (C/I/H)  1.0   0.0 2.5   0.4
7  LCMV Control Day 4 4.8   0.1 not done
mAb 1F8 (C/I/H 4.5   0.5 not done
C57BL/6 mice were treated with mAb in HBSS or HBSS control, infected with virus, and examined for PFUs in spleen or liver 3 or 4 d later. PFUs
represent either the titers per whole organ or per half organ, as in some experiments the spleens were cut in half in order to do analyses on the
leukocytes. Each experiment had a n   4 or 5 per group, except for Exp. 5, which used T cell KO mice and n   3.
The NK-resistant Armstrong strain of LCMV, which replicates poorly in liver, was used in these experiments, and for that reason liver titers were not
assessed. The dosage of mAb was 200  g of mAb 1F8 in each experiment except for experiments 4, where 50  g was used and 5, where 25  g was
used. mAb 5E6 was used at a concentration of 200  g. mAb to NK1.1 was used at dose previously determined to deplete NK cell but not CTL
activity. Results presented are geometric mean titers, that is the arithmetic averages of the log values. The limits of detection were 1 log10 PFUs in
the spleen and 2 log10 PFUs in the liver; these minimum detection values were entered into the calculations when no virus was found, and the ( )
designation means that at least one mouse had undetectable viral titers. Exp., experiment.40 Control of MCMV by an NK Cell Subset
NK cell populations, we also routinely monitored the
NK1.1 CD3  NK/T populations. During MCMV infec-
tion, the proportions of these NK/T cell populations
dropped dramatically in the liver, where they were rela-
tively high before infection (Fig. 9, bottom). Similar drops
in percents and total cell numbers of liver NK/T cells were
seen with MHV and VV, though less so with LCMV (Fig.
9, top). Thus, while prototypical NK cell numbers were
rising dramatically in infection (Fig. 1), NK/T cells were
declining dramatically. Few NK/T cells were found in the
peritoneal cavity either before or after infection. Although
some of this apparent decline could be an artifact due to
downmodulation of NK1.1 and CD3, our data, and those
of others (R. Brutkiewitz, University of Indiana, personal
communication), to be published elsewhere, indicate that
this NK/T cell population undergoes apoptosis and de-
clines in number at early stages of infection and under con-
ditions of strong IFN-inducing stimuli.
NK1.1 CD3  (NK/T) lymphocytes were analyzed for
coexpression of Ly49 molecules before and after infection.
Monitoring Ly49 expression on these populations was
sometimes difficult during infection because of high back-
ground staining with isotype-control Abs, perhaps due to
the fact that many of these cells were undergoing apoptosis.
Nevertheless, it was clear that a substantial proportion of
the NK/T cells reacted with mAb 5E6 (Ly49 C/I) and
mAb 1F8 (Ly49 C/I/H), but very few NK/T cells dis-
played the Ly49H phenotype of 1F8 5E6 . This pattern
was seen in spleen, PECs, and liver from both uninfected
and infected mice. Displayed in Fig. 10 are data for
NK1.1 CD3  NK cells from uninfected spleens, where
there is very little contamination from NK/T cells, and
data for NK1.1 CD3  NK/T cells from uninfected liver,
where the highest numbers of NK/T cells are found, mak-
ing them easier to unambiguously discriminate from proto-
typical NK cells. This shows that few if any of the NK/T
cells have a characteristic Ly49H phenotype and are likely
not to express this positively signaling ligand. In general we
have noted that some T cells, even those not expressing
NK1.1, occasionally stain with Abs to the negatively sig-
naling Ly49 molecules (Ly49 A, C/I, G2) but not to the
positively signaling molecules (Ly49 D and H; reference
37). These experiments mean that any viral enhancement
effects due to administration of the 1F8 mAb in vivo are
likely a consequence of its action on true NK cells, not
NK/T cells, as the 5E6 mAb, which has no affect on
MCMV replication, should deplete virtually all of the 1F8 
NK/T cells in vivo.
NK/T cells were also monitored for their abilities to
spontaneously synthesize IFN-  at 2 d after infection with
Figure 8. Hematoxylin and eosin staining of MCMV-infected liver sections. (A and B) C57BL/6 liver 4 d after MCMV infection. A, original magni-
fication: 20 ; B, original magnification: 60 . Note the discrete inflammatory foci (A) around hepatocytes showing MCMV-induced cytopathology (B).
(C and D) Livers from mAb 1F8-treated MCMV-infected mice. Note the absence of discrete inflammatory foci and the presence of large necrotic areas
shown by arrows in C and sometimes near the surface (D) of the liver. C, original magnification: 4 ; D, original magnification: 10 .41 Daniels et al.
MCMV. These NK1.1 CD3  cells accounted for  5%
of the IFN- –producing NK1.1  cells in the spleen,
PECs, or liver 2 d after MCMV infection; prototypical
NK1.1 CD3  true NK cells accounted for  95% of the
IFN-  production within the NK1.1  population, and
most of the IFN- –producing cells within the entire leu-
kocyte population at 2 d after infection were NK cells, e.g.,
at 2 d after infection, 90% of the total IFN- –producing
peritoneal lymphocytes were NK1.1 CD3  NK cells. Sim-
ilar dramatic enrichments in IFN-  production by the true
NK cell population were also noted in LCMV, VV, and
MHV infections. Therefore, we conclude that prototypical
NK cells are the major IFN- –producing cells early in in-
fection and that they are mediating the effects seem with
the 1F8 mAb. The experiment showing enhanced MCMV
synthesis in mAb 1F8-treated T cell KO mice (Table II) is
consistent with this conclusion.
Discussion
This is the first demonstration that the antiviral properties
of NK cells in vivo can be mediated by discrete NK cell
subsets but not by others. Our results show that the NK cell
subsets defined by mAb 1F8 substantially increase at sites of
MCMV infection and account for  80% of the IFN- –
producing cells. mAb depletion of this subset in vivo re-
sulted in substantially higher titers of MCMV (but not
LCMV or VV); depletion of no other two or even four
Ly49-expressing subsets gave comparable results (22). The
importance of different subsets in mediating other NK cell–
dependent functions, in particular that of bone marrow al-
lograft rejection, has been shown previously (21, 40). The
mechanism of NK cell subset recognition of allografts is
clarifying, at least in some aspects. NK cell subsets displaying
Ly49 receptors that are negatively signaled by MHC class I
displayed by the graft are ineffective at mediating rejection.
However, recently we have shown that NK cells lacking in-
hibitory receptors but expressing allo-MHC positive-signal-
ing receptors, such as Ly49D, are most effective at eliciting
graft rejection (40). mAb 1F8 cross-reacts between the very
closely related Ly49 C, I, and H, but costaining and in vivo
depletion experiments with mAb 5E6, which recognizes
Ly49C/I, indicated that those reactivities did not account
for the efficacy of the Ab. Hence, it is noteworthy that the
presence of a positively signaling ligand, Ly49H, may be
necessary for anti-viral activity, just as a positive-signaling
Ly49 is crucial for bone marrow rejection.
It had not been clear whether NK subset distinctions re-
ally mattered in the control of viral infections in vivo.
Bone marrow transplants display the types of molecules
(class I) known to be ligands for Ly49 molecules and other
NKRs, but virus infections are entirely different entities,
and viral replication could well be controlled by purely
nonspecific inflammatory mechanisms that have nothing to
do with NK subsets or NK cell recognition. For instance,
relatively nonspecific inflammatory mediators such as type
I IFN, TNF- , IL-2, IL-12, IL-15, and MIP-1  can con-
tribute to the activation and proliferation of NK cells and
their infiltration into tissues (41). Those NK cells may be
highly cytolytic and be nonspecifically producing copious
amounts of IFN- , which could control infection without
any form of recognition. In fact, it had been suggested that
a reason why MCMV but not LCMV is susceptible to NK
cells is that MCMV induces more IL-12, which in turn,
enables NK cells to produce more IFN-  (35, 41). This
hypothesis is challenged by the fact that in mice dually in-
fected with both MCMV and LCMV, only MCMV is
controlled by NK cells (42). Alternatively, NK cell subsets
could matter, if the virus changes the expression level of
MHC class I antigens on infected cells (43), if it qualita-
tively alters the nature of a class I molecule by the insertion
of a virus-encoded peptide (44, 45), or if the virus encodes
its own class I molecule (46). MCMV indeed does down-
regulate host MHC expression and does encode a class I
molecule, m144; experiments to date, however, have indi-
cated that its class I homologue may make MCMV more
resistant, rather than sensitive to NK cells, perhaps by in-
teracting with a negatively signaling NKR (46). The possi-
bility also exists that a virus might encode a surface glyco-
protein that directly triggers an NK cell subset, and a
substantial amount of work done before the discovery of
NKRs had indicated that many purified viral glycoproteins
can trigger NK cells (47, 48).
A strong indicator that an NK cell subset may be impor-
tant in a viral infection in vivo has been the mapping of ge-
netic resistance to the Cmv-1 locus, which lies within the
Figure 9. Reduction in NK/T cell numbers in livers of virus-infected
mice. (Top) This represents the total NK1.1 CD3  (NK/T) cell numbers
isolated from the livers of C57BL/6 mice at different days after infection
with either of several viruses. This representative experiment shows data
from pooled livers from at least three mice per group. (Bottom) This shows
NK1.1 CD3  liver leukocytes from uninfected control mice (Day 0) and
mice 2 d after MCMV infection (Day 2).42 Control of MCMV by an NK Cell Subset
NKR region of mouse chromosome 6 somewhere be-
tween Ly49D and Prp-1 (49). It is therefore possible that
the putative Cmv-1 protein is an Ly49 molecule. This lo-
cus controls the replication of MCMV mostly in the spleen
but less so in the liver (7). NK cells mediate control of
MCMV by different mechanisms in these two organs.
Replication in the liver is controlled by IFN- , whereas
replication in the spleen is controlled primarily by a per-
forin-dependent mechanism, suggesting cytotoxicity (18,
19). Our assays in this study focused only on IFN-  pro-
duction, but we presume that those 1F8  NK cells also
have cytolytic activity. Indeed, our preliminary data with
IFN- –deficient mice show that mAb 1F8 dramatically el-
evates spleen viral titers, consistent with an additional
mechanism such as perforin being involved in control of
MCMV. Depletion of the 1F8  subset in normal C57BL/6
mice affected viral titers and enhanced pathology in both
spleen and liver, an observation that may be inconsistent
with the effects of Cmv-1, which are noted mostly in the
spleen. However, the effects on viral titers were much
greater in the spleen than in the liver, possibly consistent
with the Cmv-1 phenotype. It is ironic that the effects of
mAb 1F8 are so profound in the spleen when, if anything,
the 1F8  NK cells appear to be recruited away from the
spleen and into other sites of infection. It of course is not
clear whether the reductions in viral titers within the spleen
are due to NK cells acting within the spleen or to NK cells
controlling virus before it can get into the spleen. The rela-
tionship between Cmv-1 and the studies presented here is
unclear. The Ly49H gene lies slightly outside the area in
chromosome six mapped for the Cmv-1 locus (49, 50).
Thus, it may represent another factor of resistance. How-
ever, it remains possible given the complexities of the Ly49
family of related genes that the mapping is not completely
accurate or that the 1F8 mAb cross-reacts with another as
yet undefined Ly49 molecule mapping within the region
where  Cmv-1 may lie. Of note is that the influence of
Cmv-1 is not strongly dependent on an MHC allotype, as
this C57BL/6 (H2b) mouse locus has been bred into a nor-
mally sensitive Balb/c (H2d) background and still manifests
antiviral activity (51). Balb/c mice do not normally express
Ly49H, so it would be interesting to selectively introduce
this gene into the Balb/c background and determine
whether it promotes resistance to MCMV.
Of all systems studied, MCMV remains, at least in our
hands, the virus whose control is most dependent on NK
cells. It is noteworthy that three other viruses, LCMV,
MHV, and VV, that are less sensitive to control by NK cells
also induced substantial infiltrates of 1F8  NK cells, many
of which could be shown to spontaneously produce IFN- 
on direct isolation ex vivo. High levels of IFN-  produc-
tion by NK cells in MCMV-infected mice have been linked
to the ability of MCMV to induce high levels of IL-12 early
in infection (18, 35). However, why 1F8  NK cells are so
good at producing IFN-  after viral infections does not
seem to be associated with any selective sensitivity to IL-12,
as they are the major IFN- –producing cells even in mice
lacking IL-12 p40 receptor (unpublished observations). The
total number of NK cells and the percent of NK cells pro-
ducing IFN-  is lower in IL-12R KO mice, but the 1F8 
cells remain the predominant IFN- –producing cell popu-
lation, accounting for  75% of the IFN- –producing cells.
It is possible that the positively signaling Ly49H responds to
a common property of virus-infected cells or, alternatively,
may be primed by positively stimulating ligands in the envi-
ronment even before virus infection takes place.
Figure 10. Low frequency of mAb 1F8 5E6  NK/T
cells. Prototypical NK1.1 CD3  NK cells from the
spleens of uninfected mice and NK1.1 CD3  NK/T cells
from the livers of uninfected mice (top) were costained
with mAb to 1F8 (Ly49C/I/H) or 5E6 (Ly49C/I) (bot-
tom). These leukocyte sources were selected to give the
most unambiguous data with the least amount of cellular
cross-contamination.43 Daniels et al.
Why are these NK cells so important for control of
MCMV, but less so for the other viruses? This might relate
to the fact that MCMV seemed to provide a much greater
IFN- –producing stimulus than the other viruses under the
conditions tested, but there is little question that highly ac-
tive IFN- –producing 1F8  NK cell populations were at
the sites of infection of all of those viruses. Either the other
viruses are relatively resistant to the antiviral effects of NK
cells, or else, in the absence of NK cells, the control of
those infections is efficiently compensated for by another
effector system providing innate immunity. We now know
that VV can be effectively controlled by an early    T cell
response and by memory    T cells cross-reactive with
other antigens (24, 31). Redundancy in antiviral functions
would clearly be to the advantage of the host. The mecha-
nism of the unique susceptibility of MCMV and perhaps
some other herpes viruses to control by NK cells is still in
need of resolution.
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